The strategy for prevention of measles and rubella prevalence with measles-rubella (MR) vaccine in Japan

Vaccine

Volumn 27, Issue 24, 2009, Pages 3234-3236

  Ihara, Toshiaki ^a  

^a MIE NATIONAL HOSPITAL   (Japan)

Author keywords

Elimination; Measles; MR vaccine; Rubella; Supplement vaccination

Indexed keywords

IMMUNOGLOBULIN ANTIBODY; MATERNAL ANTIBODY; MEARUBIK; MEASLES ANTIBODY; MEASLES RUBELLA VACCINE; RUBELLA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; HUMAN; IMMUNITY; INFANT; JAPAN; MEASLES; PRESCHOOL CHILD; PREVALENCE; PREVENTIVE MEDICINE; PRIMARY SCHOOL; PRIORITY JOURNAL; REINFECTION; RUBELLA; VACCINATION;

HUMANS; JAPAN; MEASLES; MEASLES VACCINE; PREVALENCE; RUBELLA; RUBELLA VACCINE; VACCINES, COMBINED;

EID: 67349286470     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.075     Document Type: Article

References (16)

1. Fine P.E.M. Herd immunity: history, theory, practice. Epidemiol Rev 15 (1993) 265-302
2. Whittle H.C., Aaby P., Samb B., Jenses H., Bennett J., and Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in west Africa. Lancet 353 (1999) 98-102
3. Samb G., Aaby P., Whittle H.C., Seck A.M.C., Rahman S., Bennett J., et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 14 (1995) 203-209
4. Lee M., Nokes D.J., Hsu H., and Lu C. Protective titers of measles neutralizing antibody. J Med Virol 62 (2000) 511-517
5. Orenstein W.A., Strebel P.M., and Hinman A.R. Building an immunity fence against measles. J Infect Dis 196 (2007) 1433-1435
6. Skendzel L.P. Rubella immunity: defining the level of protective antibody. Am J Clin Pathol 106 (1996) 170-174
7. Caceres V.M., Strebel P.M., and Sutter R.W. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis 31 (2000) 110-119
8. Hartter H.K., Oyedele O.I., Dietz K., Kreis S., Hoffman J.P., and Muller C.P. Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children. Pediatr Infect Dis J 19 (2000) 635-641
9. Ihara T, Nakano T, Kamiya H, Nii R, Isaji M. The timing of measles, rubella, mumps, and varicella vaccination according to the antibody titers in the cord blood. The survey on study group of vaccination; 2005. p. 72-4 (in Japanese).
10. Davidkin I., and Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine 16 (1998) 2052-2057
11. Lee M., Chien L., Yueh Y., and Lu C. Measles seroepidemiology and decay rate of vaccine-induced measles IgG titers in Taiwan, 1995-1997. Vaccine 19 (2001) 4644-4651
12. Amanna I.J., Carlson N.E., and Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357 (2007) 1903-1915
13. Vitek C.R., Aduddell M., Brinton M.J., Hoffman R.E., and Redd S.C. Increased protections during a measles outbreak of children previously vaccinated with a second dose of measles-mumps-rubella vaccine. Pediatr Infect Dis J 18 (1999) 620-623
14. Strebel P.M., Papania M.J., and Halsey N.A. Measles vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines (2004), Elsevier, Inc., Philadelphia 389-440
15. Markowitz L.E., Albrecht P., Rhodes P., Demonteverde R., Swint E., Maes E.F., et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Pediatrics 97 (1996) 53-58
16. Kacica M.A., Venezia R.A., Miller J., Hughes P.A., and Lepow M.L. Measles antibodies in women and infants in the vaccine era. J Med Virol 45 (1995) 227-229